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Monocytes from systemic sclerosis (SSc, scleroderma) patients and healthy African
Americans (AA) are deficient in the regulatory protein caveolin-1 leading to enhanced
migration toward chemokines and fibrogenic differentiation. While dermal fibrosis is the
hallmark of SSc, loss of subcutaneous adipose tissue is a lesser-known feature. To
better understand the etiology of SSc and the predisposition of AA to SSc, we studied
the adipogenic potential of SSc and healthy AA monocytes. The ability of SSc and
healthy AAmonocytes to differentiate into adipocyte-like cells (ALC) is inhibited compared
to healthy Caucasian (C) monocytes. We validated that monocyte-derived ALCs are
distinct from macrophages by flow cytometry and immunocytochemistry. Like their
enhanced fibrogenic differentiation, their inhibited adipogenic differentiation is reversed
by the caveolin-1 scaffolding domain peptide (CSD, a surrogate for caveolin-1). The
altered differentiation of SSc and healthy AA monocytes is additionally regulated by
peroxisome proliferator-activated receptor γ (PPARγ) which is also present at reduced
levels in these cells. In vivo studies further support the importance of caveolin-1
and PPARγ in fibrogenesis and adipogenesis. In SSc patients, healthy AA, and mice
treated systemically with bleomycin, adipocytes lose caveolin-1 and PPARγ and the
subcutaneous adipose layer is diminished. CSD treatment of these mice leads to
a reappearance of the caveolin-1+/PPARγ+/FABP4+ subcutaneous adipose layer.
Moreover, many of these adipocytes are CD45+, suggesting they are monocyte derived.
Tracing experiments with injected EGFP+monocytes confirm that monocytes contribute
to the repair of the adipose layer when it is damaged by bleomycin treatment. Our
observations strongly suggest that caveolin-1 and PPARγ work together to maintain
a balance between the fibrogenic and adipogenic differentiation of monocytes, that
this balance is altered in SSc and in healthy AA, and that monocytes make a major
contribution to the repair of the adipose layer.
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INTRODUCTION
Scleroderma (systemic sclerosis, SSc) is a complex autoimmune
disease involving fibrosis of the skin, lungs, and other organs.
An underappreciated feature of SSc is loss of subcutaneous
adipose tissue (Marangoni et al., 2015). This loss also occurs
in mice when bleomycin is used to induce skin fibrosis (Lee
et al., 2014a; Marangoni et al., 2015). As described below,
two molecules of interest in the regulation of adipogenesis
are caveolin-1 and peroxisome proliferator-activated receptor γ
(PPARγ). Interestingly, both caveolin-1 and PPARγ are among
the group of proteins in which mutations result in lipodystrophy
(Rochford, 2010).
African Americans (AA) have an increased risk of developing
SSc compared to Caucasians (C) (Tager and Tikly, 1999)
as exemplified by a younger age of disease onset, higher
probability of the more severe diffuse cutaneous disease, and
higher mortality (Laing et al., 1997; Mayes, 2003; Krishnan
and Furst, 2005; Nietert et al., 2006). While there has been a
major focus on AA SSc patients, there have been few studies
on underlying differences between healthy AA and C that
might result in this predisposition. In one study, healthy AA
were found to have twice the serum level of the profibrotic
cytokine TGFβ than healthy C (August and Suthanthiran, 2003).
We have identified several parameters in which healthy AA
are similar to SSc patients (Silver et al., 2012; Reese et al.,
2014b) which may contribute to the predisposition of AA to
SSc.
Caveolin-1, a protein associated with plasma membrane
invaginations known as caveolae and with other cellular
membranes is underexpressed on various cell types from healthy
AA and SSc patients including fibroblasts and monocytes
(Tourkina et al., 2005, 2008, 2010; Del Galdo et al., 2008).
Similarly, caveolin-1 is also deficient in mice in which skin
and lung fibrosis have been induced with bleomycin (Kasper
et al., 1998; Del Galdo et al., 2008; Tourkina et al., 2008; Lee
et al., 2014a,c). The caveolin-1 scaffolding domain peptide (CSD)
can enter cells and inhibit kinases just like full-length caveolin-
1 (Bucci et al., 2000; Bernatchez et al., 2005). Through its
ability to act as a surrogate for caveolin-1, CSD can reverse
a variety of cell behaviors associated with fibrosis in vitro
(collagen overexpression by SSc fibroblasts, enhanced migration
and enhanced fibrocyte differentiation by AA and SSc monocytes
(Tourkina et al., 2005, 2011; Reese et al., 2014b) and in vivo
(enhanced lung and dermal fibrosis, loss of subcutaneous
adipocytes, Lee et al., 2015).
PPARγ is a ligand-activated nuclear receptor that regulates
diverse aspects of lipid and lipoprotein metabolism and glucose
homeostasis (Jiang et al., 1998; Ricote et al., 1998; Evans
et al., 2004; Berger et al., 2005). In addition to expression in
adipocytes, PPARγ is expressed in endothelial cells, vascular
smooth muscle cells, monocytes/macrophages, and fibroblasts
(Collins et al., 2001; Ghosh et al., 2004). Endogenous and diet-
derived fatty acids and eicosanoids such as prostaglandin J2 are
low-affinity natural PPARγ ligands; the thiazolidenedione drugs
[e.g., rosiglitazone and troglitazone (TRO)] are potent synthetic
PPARγ agonists (Spiegelman, 1998).
Monocytes and monocyte-derived fibrocytes have been
reported to differentiate into both adipocytes and myofibroblasts
(Kuwana et al., 2003; Hong et al., 2005, 2007). Here we
have studied the differentiation of monocytes into ALCs in
fibrotic disease using both human samples (from healthy C,
healthy AA, and SSc patients) and mice treated with bleomycin
or vehicle. These studies indicate that healthy AA and SSc
monocytes are deficient in adipogenic differentiation due to
the low levels of caveolin-1 and PPARγ in these cells. Human
studies further demonstrate that monocyte-derived ALCs are
readily distinguished from macrophages. Mouse experiments
demonstrate that monocytes contribute to the subcutaneous
adipose cell layer, particularly the regeneration of this layer
following bleomycin-induced injury. In summary, these studies
support the concept that fibrotic skin disease results in part from
the fibrogenic differentiation of monocytes at the expense of their
adipogenic differentiation and that caveolin-1 and PPARγ are
two key proteins in regulating this balance.
METHODS
Blood Donors
Under a protocol approved by the Medical University of
South Carolina (MUSC) Institutional Review Board for Human
Research, SSc interstitial lung disease (ILD) patients were
recruited from the MUSC Scleroderma Clinic. All patients
provided written informed consent before enrollment in the
study and fulfilled the American College of Rheumatology
criteria for SSc (Subcommittee, 1980) and had evidence of ILD
(Tourkina et al., 2010). Demographic data for SSc patients and
healthy control donors are summarized in Tables 1, 2. Note that
Table 1 describes the combined data for all the patients that
TABLE 1 | Clinical features of SSc patients.
Race/Smoking Gender Numbers
Caucasian M 3
Caucasian F 14
African American M 0
African American F 12
Smoker 1
Former Smoker 2
C AA
Age: Mean ± SD (range) 57.9 ± 9.5 (43–75) 49.7 ± 11.7 (33–72)
Disease duration: Mean ± SD (range) 9.4 ± 5.8 (5–22) 9.3 ± 8.7 (1–28)
Limited Cutaneous 11 7
Diffuse Cutaneous 6 5
Overlap 8 9
Pulmonary Involvement (ILD) 17/17 (100%) 12/12 (100%)
Patients: SSc patients were classified as having either limited cutaneous (lcSSc) or
diffuse cutaneous (dcSSc) disease according to (Leroy et al., 1988). Disease duration
was determined based on when the first non-Raynaud’s Phenomenon symptoms were
documented. We present demographics on C and AA SSc patients separately here.
However, because in our studies we found no differences between these groups, the
data is pooled in the Results section.
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TABLE 2 | AA and caucasians controls.
Race Gender Donors Smokers Former smokers
Caucasian M 13 0 2
Caucasian F 20 1 2
African American M 4 0 1
African American F 24 1 2
Age: Mean ± SD (range); Caucasian 34.4 ± 10.9 (19-57); African American 36.6 ± 11.2
(21-57).
participated in the entire study, not the patients that participated
in a particular experiment. Healthy C and AA are studied
separately because we have previously published that there are
major differences in their monocytes in caveolin-1 levels and cell
function (Reese et al., 2014b). However, the data for C and AA
SSc patients are not separated because no differences have been
observed (Reese et al., 2014b).
PBMC and Monocyte Isolation
PBMC were isolated by standard methods (Tourkina et al.,
2010) by centrifugation on density 1.083 Histopaque cushions.
Monocytes were isolated from the PBMC by immunodepletion
using a Dynal Monocyte Negative Isolation Kit (Invitrogen,
Carlsbad, CA) resulting in a cell population about 95% Mac-
1+ monocytes (Tourkina et al., 2010), then allowed to recover
overnight in 6-well tissue culture plates (2× 106 cells per well) in
RPMI 1640/ 20% FCS.
Monocyte to ALC Differentiation
Methods were slightly modified from Hong et al. (2007) and
Kuwana et al. (2003). Briefly, PBMC were plated in six-well
fibronectin-coated plates (2 × 107 cells in 2 ml DMEM/ 20%
FCS). On day 5, ALC differentiation was initiated by incubating
the cells for 3 days in Adipocyte Induction Medium (AIM)
described by Kuwana et al. (2003) (DMEM/ 10% FBS/ 1 µM
TRO/ 1 µM Dexamethasone/ 100 µM Indomethacin/ 10 µg/ml
Insulin) followed by 1 day in Maintenance Medium (DMEM/
10% FBS/ 10 µg/ml Insulin). The cycle of “3 days on, 1 day
off” was repeated and cells were harvested on day 13 cells. For
CSD treatment, the medium was supplemented on days 2, 5, and
9 with a final 0.1 µM CSD (amino acids 82–101 of caveolin-
1 (DGIWKASFTTFTVTKYWFYR-NH2) purchased from Elim
Biopharmaceuticals). When treating cells with CSD, a stock
solution (10 mM in 100% DMSO) was diluted to the indicated
final concentration.
For staining, the same methods were used except that the
wells contained fibronectin-coated coverslips. For Western blots,
cells were extracted with the Lysis Buffer described below.
Staining and Western blotting were performed as described
below.
Monocyte to Macrophage Differentiation
PBMC were plated in six-well tissue culture plates (1 × 107 cells
in 2 ml Monocyte Attachment Medium [Promocell]) for 1.5 h.
The medium and unbound cells were removed and bound cells
further incubated in Supplemented Basal Medium (Promocell)
+M-CSF or GM-CSF (100 ng/ml). 1 ml fresh medium is added
at day 6 (plus M-CSF or GM-CSF) and again at day 9. Cells are
harvested on day 11 and analyzed by immunocytochemistry and
flow cytometry (Reese et al., 2014a).
Treatment of Monocytes
After isolation and recovery as described above, cells were treated
for 3 h in RPMI/ 1% BSA supplemented with 0.1 µM CSD
or TRO (1 µM). In some experiments, cells were pretreated
with TGFβ for 45 min. After incubation, cells were washed
with cold PBS and extracted with Lysis Buffer (20 mM Tris-
HCl (pH 7.5)/ 1% NP-40/ 100 mM NaCl/ 5 mM EDTA/ 2 mM
KCl) supplemented with 1 mM phenylmethylsulfonyl fluoride,
protease inhibitor mixture Set V (Calbiochem), and phosphatase
inhibitors (10 mM sodium pyrophosphate, 5 mM NaF, 10
mM beta-glycerophosphate, and 10 mM sodium orthovanadate).
For staining, the same methods were used except that the
wells contained coverslips. Staining and Western blotting were
performed as described below.
Staining
Cells on coverslips were fixed with 4% paraformaldehyde, then
stained with Oil Red O or blocked for 24 h with PBS/ 5% BSA/
0.1% Triton X-100 then stained immunocytochemically using
the indicated primary antibodies (Table 3) and appropriately
conjugated secondary antibodies. Nuclei were counterstained
using DAPI.
Western Blotting
Protein concentrations in Lysis Buffer extracts were measured
using the BCATM Protein assay kit (Pierce). Up to 40 µg of total
protein was loaded per lane. Western blotting was performed
by routine methods using the indicated primary antibodies
(Table 3).
Mouse Experiments
These studies were performed under protocols approved by
the MUSC Institutional Animal Care & Use Committee. (1)
Treatment of mice with bleomycin and CSD: Mice were treated
systemically with bleomycin (Cipla, Mumbai, India) (67 U/kg)
or vehicle and received CSD or vehicle as recently described
(Lee et al., 2014a,b). Skin tissue sections were then stained with
the indicated antibodies. (2) Injection of Monocytes Isolated
from EGFP ± Mouse Bone Marrow: EGFP+ mice (Jackson
Laboratory) were treated with bleomycin or vehicle as described
above. On day 21, mice were sacrificed and monocytes were
isolated from bone marrow: Femurs and tibias were dissected,
scissors were used to gently snip off the ends of the bones, and BM
cells were flushed out using MACS buffer (PBS [pH 7.2]/ 0.5%
BSA/ 2 mM EDTA) delivered with a syringe and a 26G needle.
The cells were disaggregated by gentle pipetting, then passed
through a 40 µm cell strainer to remove residual cell clumps
or debris. Cells were washed with MACS buffer and collected
by centrifugation (300 × g, 10 min). Finally, monocytes were
enriched by negative selection using a MACSMonocyte Isolation
Kit (BM) mouse (130-100-629) following the manufacturer’s
protocol. The purity of the isolated monocytes was confirmed by
flow cytometry. Of particular note, the cells were almost 100%
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TABLE 3A | Antibodies Used in Western Blotting.
Target Source Type
Human PPARγ Cell Signaling #2435 Rabbit monoclonal
Human Caveolin-1 Santa Cruz sc-894 Rabbit polyclonal
Human FABP4 EMD Millipore MABS172 Rabbit monoclonal
Human GAPDH EMD Millipore MAB374 Mouse monoclonal
TABLE 3B | Antibodies Used in Immunocytochemistry,
Immunohistochemistry, and Flow Cytometry.
Target Source Type
Mouse PPARγ Abcam ab59256 Rabbit polyclonal
Mouse Caveolin-1 Santa Cruz sc-894 Rabbit polyclonal
Mouse Caveolin-1 BD Biosciences 610057 Mouse monoclonal
Mouse FABP4 Abcam ab93945 Mouse monoclonal
Mouse FABP4 EMD Millipore MABS172 Rabbit monoclonal
Mouse CD45 BD Biosciences 553076 Rat monoclonal
Human PPARγ Abcam ab59256 Rabbit polyclonal
Human Caveolin-1 Santa Cruz sc-894 Rabbit polyclonal
Human Caveolin-1 BD Biosciences 610057 Mouse monoclonal
Human CD45 eBioscience 14-0459 Mouse monoclonal
Human FABP4 Abcam ab93945 Mouse monoclonal
Human CD14 Santa Cruz sc-9150 Rabbit polyclonal
Human CD163 Santa Cruz sc-20066 Mouse monoclonal
Human iNOS BD Transduction Lab 610432 Mouse monoclonal
Human Arginase eBioscience 14-9779-82 Mouse monoclonal
Human CD206 Santa Cruz sc-376232 Mouse monoclonal
CD45+, CD11b+, CD68+, CD73−, CD90−, and CD105−.
Therefore, the population does not containmesenchymal stromal
cells (which are CD45−, CD73+, CD90+, and CD105+). Finally,
cells (5 × 105) in 200 µl PBS were injected into host mice (10
days after the initiation of bleomycin or vehicle treatment) via
the retro-orbital sinus. Mice were sacrificed on day 28, skin tissue
sections prepared, and analyzed by Masson’s Trichrome Staining
and fluorescence microscopy to detect EGFP+ cells and FABP4
by immunohistochemistry.
Immunohistochemistry of Mouse and
Human Tissue Sections
Immunohistochemistry of skin tissue sections was performed
as described (Tourkina et al., 2011). Briefly, paraffin sections
were stained using the indicated primary antibodies (Table 3),
appropriate conjugated secondary antibodies, and the nuclear
stain DAPI (Invitrogen, Carlsbad, CA).
Statistical Analyses
Immunoreactive bands were quantified by densitometry using
Image J 1.32 NIH software. Raw densitometric data were
processed and analyzed using Prism 3.0 (GraphPad Software
Inc.) and normalized vs. data obtained with GAPDH as the
loading control. T-test or one-way ANOVA with Tukey’s
correction post-hoc was used as appropriate to evaluate Western
blots. p < 0.05 was considered as a statistically significant
difference. In all figures, ∗∗∗ indicates p < 0.001, ∗∗ indicates p
< 0.01, and ∗ indicates p< 0.05.
RESULTS
We previously demonstrated that monocytes from SSc patients
and healthy AA exhibit enhanced fibrogenic differentiation due
to a deficiency in caveolin-1 that can be functionally reversed
by treating the cells with CSD which serves as a surrogate for
caveolin-1 (Reese et al., 2014b; Lee et al., 2015). Given that dermal
fibrosis is associated with a loss of subcutaneous adipocytes both
in SSc patients and in a mouse model for SSc (Lee et al., 2014a;
Marangoni et al., 2015), here we have determined whether SSc
and AA monocytes are also altered in their ability to differentiate
into lipid-containing, FABP4+ cells which for simplicity we refer
to as ALCs. Although other monocyte derivatives (macrophages)
can accumulate lipid and express FABP4 (Tontonoz et al., 1998;
Jiang et al., 2013; Lázaro et al., 2013; Dubland and Francis, 2015),
we will show that ALCs derived from control monocytes contain
much higher levels of FABP4 than do macrophages differentiated
from monocytes from the same donor.
Decreased ALC Differentiation by SSc and
Healthy AA Monocytes
Our method for studying monocyte differentiation into ALCs in
vitro is modified from (Hong et al., 2007) and (Kuwana et al.,
2003). ALC differentiation is evaluated in terms of histochemical
staining with the lipid dye Oil Red O, immunocytochemical
(ICC) staining for the adipocyte marker fatty acid binding
protein 4 (FABP4), Western blotting, and flow cytometry.
Following treatment with Adipocyte Induction Medium
(AIM), almost 100% of C cells are large and round with lipid
droplets brightly stained with Oil Red O while such cells rare
among AA and SSc cells (Figure 1A, Table 4). When ALC
differentiation was detected by FABP4 staining (Figures 1B–D),
no stained cells were observed under Control conditions (even
among C cells). With induction of adipogenesis, the number of
FABP4+ cells detected by ICC is much higher in C cells than
among AA or SSc cells (Figures 1B–D, Table 4) indicating that,
in accord with the Oil Red O staining, adipocyte differentiation is
deficient among AA and SSc monocytes.
To distinguish adipocyte differentiation from macrophage
differentiation, monocytes from the same donor were treated
with AIM to induce adipocyte differentiation or with M-
CSF or GM-CSF to induce macrophage differentiation. Despite
their common origin, the markers expressed following these
treatments are very different (Figure 2). ALCs are strongly
FABP4+ while macrophages are CD163+, iNOS+, arginase+,
CD206+ depending on whether they were induced with M-CSF
or GM-CSF, and are routinely CD14+ (Kuwana et al., 2003).
In contrast, ALCs are CD14−, CD163−, CD206−, arginase−,
and iNOS−. Because it has been reported that macrophages
(particularly foam cells) can be FABP4+ (Jiang et al., 2013;
Lázaro et al., 2013), we quantified FABP4 levels by flow cytometry
(Figure 2). While macrophages contain FABP4, its level in ALCs
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FIGURE 1 | Monocyte Differentiation into ALCs. PBMC from healthy C, healthy AA, and SSc patients were incubated in medium that promote ALC differentiation
(AIM) or in Control medium lacking additives. (A) Cultures were stained with Oil Red O to detect ALCs. Similar results were obtained in three independent experiments.
(B) Healthy C, (C) healthy AA, and (D) SSc patient cultures were supplemented with CSD on days 2, 5, and 9. Cultures were stained for FABP4 to detect ALCs.
Similar results were obtained in three independent experiments. (E) Lysis Buffer extracts of the indicated cultures from healthy C donors (B) were Western blotted with
the indicated antibodies. GAPDH served as a loading control. (F,G) Western blots (n = 4 independent experiments using cells from different subjects) performed as in
(E) were quantified densitometrically (average ± s.e.m.) normalized against GAPDH. In (F) the level of PPARγ in Control cultures was set to 100 Arbitrary Units. In (G)
the level of FABP4 in AIM cultures was set to 100 Arbitrary Units. ***p < 0.001, *p < 0.05 vs. Control; @p < 0.05 vs. AIM.
was much higher, indicating that FABP4 can be used as an ALC
marker.
Roles of Caveolin-1 and PPARγ
Given that CSD, by acting as a surrogate for caveolin-1, reverses
the enhanced ability of AA and SSc monocytes to differentiate
into fibrocytes (Reese et al., 2014b), we hypothesized that CSD
might also reverse the decreased ability of AIM-treated AA
and SSc monocytes to differentiate into ALCs. Indeed, ICC
(Figures 1D,E, Table 4) experiments demonstrated an increased
number of large, round FABP4+ cells derived from AA and
SSc monocytes in the presence of CSD. The ability of CSD to
enhance ALC differentiation is also observed for C monocytes,
both in ICC (Table 4) and Western blotting experiments for
FABP4 (Figures 1E,G).
To determine whether a deficiency in PPARγmight contribute
to the decreased ability of AA and SSc monocytes to differentiate
into ALCs, we examined PPARγ levels in freshly isolated
monocytes. Like caveolin-1, PPARγ levels were low in healthy
AA monocytes and lower still in SSc monocytes determined
both by Western blotting (Figure 3A) and ICC (Figure 3C).
PPARγ levels were increased during a 1-h treatment with
CSD (Figure 3B), suggesting that caveolin-1 regulates PPARγ
accumulation. This conclusion is further supported by long-term
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TABLE 4 | ALC Differentiation Detected by Oil Red O and FABP4 Staining.
PBMC Oil Red O Stain FABP4 Stain
Treatment Treatment
AIM Control CSD AIM AIM + CSD
C 30.0 ± 3.7 1.3 ± 0.5 2.3 ± 0.5 29 ± 6 40.0 ± 3
AA 4.4 ± 2.0*** 0.6 ± 0.1 1.23 ± 0.05 7.6 ± 2.0* 21.3 ± 4**,@@
SSc 3.9 ± 2.8*** 0 ± 0 1 ± 0.3 4.3 ± 0.3* 15.0 ± 1**,@@@
The results of three independent experiments performed as in Figure 1A (for Oil Red O
staining) and as in Figures 1B–D (for FABP4 staining) were quantified in terms of positive
cells per field, six fields per subject. ***p < 0.001, **p < 0.01, *p < 0.05 for AA or SSc
vs. C in each category; @@@p < 0.001, @@p < 0.01 for AIM + CSD vs. AIM. Statistical
analyses are not presented for the small number of positive cells under Control and CSD.
ALC differentiation experiments in which CSD increased PPARγ
levels in ALCs derived from C monocytes (Figures 1E,F).
Conversely, we evaluated the effect of the activation of PPARγ by
a short-term treatment with TRO on caveolin-1 and PPARγ levels
(Figure 4). While TRO significantly increased both caveolin-
1 and PPARγ levels in SSc monocytes, it had an intermediate
effect on AA monocytes, and little or no effect on caveolin-1
and PPARγ in C monocytes. Finally, because we have shown
that a short-term TGFβ treatment decreases caveolin-1 levels
in C monocytes (Tourkina et al., 2010), we evaluated its effect
on PPARγ levels. While TGFβ has been reported to decrease
PPARγ levels in other cell types (Wei et al., 2010), it slightly
increased PPARγ levels in C and AA monocytes (although
this effect was not statistically significant) (Figures 4C,D). The
combined results suggest that while both caveolin-1 and PPARγ
are present at reduced levels in AA and SSc monocytes, these are
independent effects.
Low PPARγ and Caveolin-1 Levels in
Healthy AA and SSc Patient Adipocytes
in vivo
To determine whether the low PPARγ and caveolin-1 expression
observed in healthy AA and SSc patient monocytes might
also carry over into adipocytes, tissue sections were double-
stained for caveolin-1 and PPARγ. Observations at the level
of the subcutaneous adipose cell layer demonstrate that while
coincident ring staining was observed in healthy C adipocytes,
little staining was observed in healthy AA and SSc patient
adipocytes (Figure 5). It was also noteworthy that healthy AA
and SSc patient adipocytes have a smaller diameter than healthy
C adipocytes. Thus, the low caveolin-1/ low PPARγ phenotype
of AA and SSc monocytes (that differentiate poorly into ALCs)
is shared by the poorly differentiated subcutaneous adipocytes
observed in AA and SSc.
PPARγ and Caveolin-1 Levels in
Adipocytes in the Mouse Model
To evaluate the relationship between fibrosis and adipogenesis in
vivo, we used a mouse model system in which systemic treatment
with bleomycin results both in dermal fibrosis and a thinning
of the subcutaneous adipose layer (Lee et al., 2014a). Because
caveolin-1 and PPARγ expression are low in monocytes with low
adipogenic potential (Figure 3), we examined their expression
in the mouse model. In control mice, caveolin-1 and PPARγ
were coincidently expressed in adipocytes at high levels in a
peripheral ring (Figure 6) similar to what we observed in human
C adipocytes (Figure 5). When mice are treated with bleomycin,
caveolin-1 and PPARγ (Figure 6) are strikingly decreased in
the few, small adipocytes that remain (similar to SSc patients,
Figure 5). When the mice receive CSD in addition to bleomycin,
while the diameter of adipocytes was still somewhat smaller than
in control animals, the number of adipocytes is restored to almost
the control level and their expression of caveolin-1 and PPARγ is
at least as high as in control animals. These observations confirm
the importance of caveolin-1 and PPARγ in the balance between
fibrosis and adipogenesis both in vitro and in vivo.
Fibrosis and Loss of Subcutaneous
Adipocytes in a Mouse Model System
To determine whether hematopoietic cells are precursors of
adipocytes, skin sections were double-labeled with FABP4 and
CD45 (Figure 7). Control mice (no bleomycin/no CSD) showed
punctate staining for CD45 and fine ring staining of adipocytes
for FABP4. When mice were treated with CSD alone, FABP4
staining was enhanced while CD45 staining remained punctate.
When mice were treated with bleomycin alone, in accord with
the loss of the adipose layer observed histochemically (Lee et al.,
2014a), there was almost no FABP4 staining while CD45 staining
was again punctate. Finally, when mice received both bleomycin
and CSD, FABP4 staining was enhanced and in some cells
FABP4 ring staining coincided with CD45 ring staining, although
punctate CD45 staining was also observed. While it is likely
that punctate CD45 staining represents macrophages, cells with
coincident ring staining with FABP4 and CD45 may be BM-
derived adipocytes that contribute to the repair of the injured
adipose layer (Bleomycin + CSD), but do not appear in the
uninjured adipose layer.
To confirm the contribution of hematopoietic cells to
regeneration of the subcutaneous adipose layer, we traced the
fate of EGFP+ monocytes introduced into the circulation of
bleomycin-treated and vehicle-treated mice. These “green”
cells (which could only have been derived from the injected
monocytes) became FABP4+ and incorporated into the
adipocyte layer of bleomycin-treated mice much more
extensively than they incorporated into the adipocyte layer
of vehicle-treated mice (Figure 8) (p < 0.01). While this
regenerative effect was observed both with injected EGFP+
monocytes derived from vehicle-treated and bleomycin-treated
mice, this beneficial effect was somewhat greater with vehicle-
treated monocytes (Figure 8). Moreover, the coincident EGFP
and FABP4 staining was more ring-like when the injected
cells were from control mice and was more punctate when the
injected cells were from bleomycin-treated mice. It has been
suggested that ring staining of adipocytes with BM markers is
due to a crown of macrophages surrounding necrotic adipocytes
(Cinti et al., 2005; Berry and Rodeheffer, 2013). This viewpoint
was supported by showing multiple nuclei in the ring (Berry and
Rodeheffer, 2013). While we observe some punctate staining
that represents macrophages in Figure 8 (examples are marked
with arrowheads), we also detect coincident EGFP/FABP4 ring
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FIGURE 2 | Monocyte-Derived Macrophages and ALCs Carry Distinct Markers. As described in the Methods, monocytes were induced to differentiate into
ALCs using AIM or into macrophages using GM-CSF or M-CSF. Cells were then stained using the indicated antibodies and with DAPI. In each panel of four images,
those on the left shows FABP4 + DAPI and those on the right show the indicated macrophage marker + DAPI. (Lower right) FABP4 levels in the indicated cell
populations were determined by flow cytometry. Results are representative of three repeats in each category.
staining (an example is marked with an arrow) without multiple
nuclei, suggesting that the coincident ring staining is due to BM-
derived cells that express high levels of FABP4, not BM-derived
macrophages that surround FABP4+ cells. Thus, while there are
BM-derived macrophages in subcutaneous adipose tissue in all
cases, we propose that repair of bleomycin-induced injury occurs
due to the differentiation of healthy monocytes into ALC.
When the same sections were stained with Masson’s
Trichrome, as expected, bleomycin treatment reduced the
thickness of the subcutaneous adipose layer and this effect was
reversed in mice injected with either healthy monocytes or
monocytes from bleomycin-treated mice (Figure 9). While the
data shown in Figure 9 suggest that monocyte injection decreases
the thickness of the dermis, the effect was not statistically
significant.
DISCUSSION
Here we report several novel observations regarding monocytes
and altered adipogenesis in fibrotic disease including: (1) SSc
monocytes and healthy AA monocytes have a decreased ability
to differentiate into adipocytes in vitro compared to healthy C
monocytes both in the absence and the presence of TRO (a
synthetic PPARγ ligand that induces adipocyte differentiation);
(2) Healthy AA and SSc monocytes and healthy AA and
SSc adipocytes (in vivo) are deficient in both caveolin-1 and
PPARγ; (3) CSD enhances both ALC differentiation by C,
AA, and SSc monocytes in vitro and PPARγ expression; (4)
When mice are treated systemically with bleomycin, dermal
fibrosis occurs, adipocytes lose caveolin-1 and PPARγ (as in
SSc patients and healthy AA), and the subcutaneous adipose
layer shrinks; (5) CSD treatment of bleomycin-treated mice
promotes subcutaneous adipogenesis and the expression of
PPARγ in adipocytes (just as it promotes PPARγ expression
in SSc and AA monocytes and their differentiation into
ALCs); (6) Many of the cells involved in the repair of the
bleomycin-injured adipose layer are BM-derived monocytes
as evidenced by their expression of CD45 and by the
contribution of injected EGFP+ monocytes to the adipose
layer.
Our studies and the literature indicate several connections
between caveolin-1 and PPARγ that may be relevant to the
balance between fibrosis and adipogenesis. Both caveolin-1
and PPARγ are present at low levels in monocytes from
SSc patients and healthy AA that exhibit an enhanced ability
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FIGURE 3 | Low Caveolin-1 and PPARγ in AA and SSc Monocytes. (A) (bottom) Representative Western blot of PPARγ and GAPDH (loading control) in C, AA,
and SSc monocytes. (top) Densitometric quantification. Each symbol represents the value in arbitrary units normalized against GAPDH from one person. (B) (bottom)
Representative Western blot showing effect of CSD on PPARγ levels and (top) densitometric quantification (average ± s.e.m.) normalized against GAPDH combining
data from three independent experiments using cells from different subjects. The PPARγ level in C monocytes not treated with CSD was set to 100 arbitrary units. (C)
Demonstration by ICC of decreased expression of caveolin-1 and PPARγ by AA and SSc monocytes. C, AA, and SSc monocytes were stained green for caveolin-1
(Cav-1) and red for PPARγ. Nuclei were counterstained using DAPI (blue). Representative images are shown that are typical of the results obtained in four independent
experiments in each category. *p < 0.05, **p < 0.01.
to differentiate into fibrocytes/myofibroblasts (Reese et al.,
2014b) and an inhibited ability to differentiate into adipocytes
(Figure 1). SSc and AA subcutaneous adipocytes (Figure 5)
and SSc fibroblasts are also deficient in caveolin-1 and
PPARγ (Tourkina et al., 2005; Del Galdo et al., 2008; Wei
et al., 2010). Both caveolin-1 and PPARγ are among the
group of proteins in which mutation results in lipodystrophy
(Rochford, 2010). Both are downregulated in cultured adipocytes
during bacterial infection (Nagajyothi et al., 2008) and in
a variety of cell types by TGFβ treatment (Wang et al.,
2006; Tourkina et al., 2010; Wei et al., 2010). However,
data from our lab and others suggests that TGFβ does
not decrease PPARγ levels in monocytes (Figure 4, Kintscher
et al., 2002). Caveolin-1 and PPARγ can also regulate each
other’s expression and/or activation. CSD (which acts as a
surrogate for caveolin-1) increases PPARγ levels in C, AA, and
SSc monocytes (Figure 4). Caveolin-1 can activate PPARγ in
HEK293 cells (Burgermeister et al., 2011). Overexpression of
PPARγ or its activation by rosiglitazone or TRO can increase
caveolin-1 expression in THP-1 cells (Llaverias et al., 2004) and
peripheral blood monocytes (especially AA and SSc monocytes,
Figure 4).
We previously observed that the differentiation in vitro
of monocytes into fibrocytes/myofibroblasts is enhanced in
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FIGURE 4 | Effects of TRO and TGFβ on Caveolin-1 and PPARγ Levels in C, AA, and SSc Monocytes. Isolated C, AA, and SSc monocyes were incubated for
1 h in DMEM/20% FCS (Control) or in medium supplemented with TRO, then extracted and Western blots performed with antibodies against PPARγ, caveolin-1, or
GAPDH (loading control). Representative Western blots are shown for Control vs. TRO (called TRO – and +) (D) and Control ± TGFβ (called TGFβ – and +) (E).
Densitometric quantifications (average ± s.e.m.) normalized against GAPDH combining data from three independent experiments using cells from different subjects
are shown in: (A) Caveolin-1 quantification from (D). Level in Control C monocytes set to 100 Arbitrary Units. (B) PPARγ quantification from (D). Level in Control C
monocytes set to 100 Arbitrary Units. (C) PPARγ quantification from (E). Level in Control (TGFβ-) monocytes set to 100 Arbitrary Units. *p < 0.05, **p < 0.01, ***p <
0.001.
FIGURE 5 | Low Caveolin-1 and PPARγ Levels in the Subcutaneous
Adipose Layer in Healthy AA and SSc Patients. Caveolin-1 (red) and
PPARγ (green) staining are shown at the level of the subcutaneous adipose
cell layer. Nuclei were counterstained using DAPI (blue). Similar results were
obtained in three independent experiments.
cells from healthy AA and SSc patients compared to healthy
C and must be due to the relative lack of caveolin-1 in
these cells in that it is inhibited by CSD (Reese et al.,
2014b). Here we report that, conversely, the differentiation
in vitro of monocytes into ALCs is inhibited in cells from
healthy AA and SSc patients compared to healthy C. This
difference is observed both in the presence or absence of
TRO (which promotes ALC differentiation). Moreover, just as
CSD inhibits the enhanced fibrogenic differentiation of AA
and SSc monocytes, it enhances their adipogenic differentiation
suggesting that caveolin-1 both inhibits fibrosis and promotes
adipogenesis. The same molecular mechanisms are likely to
be enhancing the fibrogenic differentiation and inhibiting the
adipogenic differentiation of AA and SSc monocytes, given that
both AA and SSc monocytes are deficient in both caveolin-1 and
PPARγ. Besides their direct effects on monocyte differentiation,
the ability of caveolin-1 and PPARγ to work together to regulate
monocyte differentiation may be enhanced because experiments
with CSD and TRO indicate that each of these proteins positively
regulates the expression of the other in monocytes.
Because macrophages can express FABP4 (Jiang et al.,
2013; Lázaro et al., 2013), expression of FABP4 is not a
sufficient criterion to identify cells as adipocytes. Therefore,
we determined the phenotype of our AIM-induced ALCs in
comparison macrophages polarized using either M-CSF or GM-
CSF (Figure 2). While we confirmed that macrophages express
FABP4, the level of expression of FABP4 was much higher
in ALCs than in macrophages. Moreover, macrophages were
positive for CD14, CD163, CD206, Arginase, and iNOS while
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FIGURE 6 | Low Caveolin-1 and PPARγ Levels in the Subcutaneous
Adipose Layer in Fibrotic Mouse Skin. Mice were treated with Bleomycin
or Saline Vehicle and with CSD or PBS Vehicle (Lee et al., 2014a) as indicated.
Sections were stained by IHC using anti-Caveolin-1 (red), anti-PPARγ (green),
and with DAPI (blue) to detect nuclei. Staining at the level of the subcutaneous
adipocyte layer is shown. Similar results were obtained in three independent
experiments.
ALCs were negative. Our data are in agreement with the work
of Kuwana’s group on the differentiation of CD14+ monocytes
into adipocytes accompanied by the loss of CD14 (Kuwana et al.,
2003). Thus, it is not necessary to isolate CD14- monocyte-
derived fibrocytes (Hong et al., 2005) in order to differentiate
monocyte-derived cells into adipocytes.
Just as CSD partially reverses the inhibition of adipogenic
differentiation of AA and SSc monocytes in vitro (Figure 1), it
has analogous effects in vivo on mice treated systemically with
bleomycin. We previously showed that, in addition to thickening
of the dermis, mice treated systemically with bleomycin lose
subcutaneous fat and that these effects are blocked by CSD (Lee
et al., 2014a). Monocytes and monocyte-derived fibrocytes have
been shown to be precursors for several cell types including
fibrocytes and adipocytes (Kuwana et al., 2003; Hong et al.,
2005, 2007). Here we have extended our previous studies to
show that, in mouse subcutaneous adipose tissue treated with
bleomycin, almost no FABP4+ cells are observed. However,
when mice receive bleomycin followed by CSD, a high level of
FABP4 ring staining of adipocytes is observed that appears to
coincide with CD45 ring staining in some cells (Figure 7). It has
been proposed that under pathological conditions (e.g., obesity),
coincident CD45/FABP4 ring staining occurs that is due to a
crown of macrophages surrounding necrotic adipocytes (Cinti
et al., 2005; Berry and Rodeheffer, 2013). While we observed
individual macrophages in Figure 7 and we observed coincident
CD45/FABP4 ring staining, we did not observe multiple nuclei
FIGURE 7 | FABP4 Staining in the Subcutaneous Adipose Layer. Mice
were treated with Bleomycin or Saline Vehicle and with CSD or PBS Vehicle
(Lee et al., 2014a) as indicated. Sections from these mice were stained by IHC
using anti-FABP4 (red), CD45 (green) and with DAPI (blue) to detect nuclei.
Staining at the level of the subcutaneous adipocyte layer is shown. Similar
results were obtained in three independent experiments.
in the rings, suggesting that they are not crowns but are double-
positive adipocytes.
To further evaluate the possibility that BM-derived cells
contribute to the repair of injury to the subcutaneous adipose
layer, we injected EGFP+ BM into control mice and mice
treated with bleomycin. Injection of EGFP+ BM has previously
allowed the demonstration that these cells can differentiate into
adipocytes in vivo in mice receiving a high-fat diet or treated
with rosiglitazone (Crossno et al., 2006). However, these authors
drew the conclusion that their EGFP+ adipocytes were derived
from mesenchymal stromal cells (and not macrophages) because
their EGFP+ adipocytes were CD45−/CD11b−. When we used
this approach (Figure 8), we also observed that the injected
cells appear to differentiate into FABP4+ adipocytes, not a
multinucleate crown of macrophages. We conclude that our
results further validate the contribution of monocytes to the
recovery of the subcutaneous adipose layer from bleomycin-
induced injury.
In agreement with our observations in Figure 7, when we
injected EGFP+ monocytes we observed a major contribution
of these cells to the adipose layer in bleomycin-treated mice
but not in control mice. There are several reasonable potential
explanations for the discrepancy between our results and those
of Crossno et al. (2006) (1) The models are different (bleomycin
treatment vs. high-fat diet or treatment with rosiglitazone), (2)
The adipose tissues being studied are different (subcutaneous
vs. omental or dorsal intracapsular brown fat), (3) Crossno
et al. (2006) isolated adipocytes by flotation. The adipocytes
in the subcutaneous fat of bleomycin-treated mice injected
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FIGURE 8 | EGFP+/FABP4+ Cells in the Subcutaneous Adipose Layer. As described in the Methods, recipient mice, and donor mice were treated with
bleomycin or saline vehicle. Monocytes were isolated from the BM of donor mice and injected into the circulation of recipient mice. After sacrifice, EGFP+ cells,
FABP4+ cells, and DAPI+ nuclei in skin tissue sections were imaged by fluorescent microscopy for each of the indicated combinations of host mice and donor cells.
The number of cells per field that contained EGFP+/FABP4+ ring staining of the adipocyte plasma membrane is indicated (three mice per condition, six fields per
mouse).
with monocytes are relatively small (Figure 9A) and may not
float, (4) Crossno et al. (2006) appears to have performed flow
cytometry using live cells. We find that certain cell types need
to be fixed and permeabilized to reveal CD45 staining (not
shown). (5) It is possible that Crossno et al. (2006) do not detect
CD45 on their EGFP+ adipocytes because the progenitors
may have lost CD45 during adipocyte differentiation as has
been observed during the differentiation of monocytes into
adipocytes in vitro (Kuwana et al., 2003). In any case, we are
confident that the cells that we injected that differentiate
into adipocytes are monocytes and not mesenchymal
stromal cells because they have the proper phenotype
(CD45+/CD11b+/CD68+/CD73−/CD90−/CD105−).
We have also extended our previous studies to examining
the levels of caveolin-1 and PPARγ in subcutaneous adipose
tissue. Coincident ring staining is observed in control tissue.
Both caveolin-1 and PPARγ are almost totally lost due to
bleomycin treatment; however, CSD treatment after bleomycin
restores the coincident ring staining of caveolin-1 and PPARγ.
The combined observations suggest that adipocytes are derived
to a large extent from hematopoietic cells, that skin fibrosis
may result from an altered balance in the differentiation of
monocytes into fibrocytes/myofibroblasts and adipocytes, and
that caveolin-1 and PPARγ are key players in regulating this
balance.
Interestingly, the injection of BM-derived monocytes also
resulted in a significant recovery in the thickness of the
subcutaneous adipose layer (Figure 9). Besides using bleomycin-
treated and vehicle-treated mice as recipients of EGFP+ cells,
we also compared the function of EGFP+ cells from bleomycin-
treated and vehicle-treated mice as the donor cells. EGFP+
cells from vehicle-treated mice were marginally more effective
in incorporating into the adipose layer. The importance of
these differences between EGFP+ cells from bleomycin- and
vehicle-treated mice will require further study. It may be that
when the bleomycin BM monocytes are taken out of the
fibrotic environment and cultured overnight, they lose their pro-
fibrotic phenotype in this assay. This could be analogous to
the situation that occurs when scleroderma patients are injected
with autologous adipose-derived mesenchymal stem cells and
beneficial effects are observed, despite the fact that these cells
are derived from an individual (the patient himself) with fibrotic
disease (Christopeit et al., 2008; Guiducci et al., 2010; Keyszer
et al., 2011; Scuderi et al., 2013). Finally, it should be noted
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FIGURE 9 | Thickness of the Dermis and the Subcutaneous Adipose
Layer in Mice Injected with BM-Derived Monocytes. Skin tissue sections
from the mice described in Figure 8 as well as host mice treated with
(Continued)
FIGURE 9 | Continued
bleomycin or saline and receiving no cell injection were stained using
Massons’ Trichrome Stain and the thickness of the dermis and the
subcutaneous adipose layer measured (three mice per category, six sites per
mouse). (A) Representative images of Massons’ staining, (B) Quantification of
thickness of dermis, (C) Quantification of thickness of subcutaneous adipose
layer. *p < 0.05 compared to bleomycin-treated mice receiving no injection.
that, while few in number, there are previous publications
indicating a beneficial effect of monocyte injection (e.g., injection
of monocytes resulted in clearance of plaques in a model of
Alzheimer’s disease, Hohsfield and Humpel, 2015).
In summary, the current study strongly supports and extends
our observations on the role of monocytes and cells derived from
monocytes (e.g., fibrocytes/myofibroblasts and adipocytes) in
skin fibrosis and on the predisposition of AA to fibrotic diseases.
Our findings highlight the idea that signaling molecules that
regulate monocyte differentiation (e.g., caveolin-1, PPARγ) are
promising targets for novel treatments for fibrotic diseases such
as SSc. In particular, CSD reverses both the enhanced fibrogenic
differentiation of monocytes and their inhibited adipogenic
differentiation both in vitro and in vivo. The physiological
relevance of the results of this study is strongly supported by
the similarity in the observations we have made in human and
mouse tissues. We observed a thinning of the subcutaneous
adipose cell layer in healthy AA, SSc patients, and in mice
treated systemically with bleomycin. Moreover, in all these
cases the remaining adipocytes were deficient in both caveolin-
1 and PPARγ. Together these observations strongly suggest
that caveolin-1 and PPARγ work together to maintain the
proper balance between the differentiation of monocytes into
myofibroblasts and adipocytes, and that fibrotic disease results
when this balance is upset to favor myofibroblast differentiation.
ETHICS STATEMENT
This study was carried out in accordance with the
recommendations of the Medical University of South Carolina
Institutional Review Board for Human Research with written
informed consent from all subjects. All subjects gave written
informed consent in accordance with the Declaration of Helsinki.
The protocol was approved by the Medical University of South
Carolina Institutional Review Board for Human Research. This
study was carried out in accordance with the recommendations
of the Medical University of South Carolina Institutional Animal
Care and Use Committee. The protocol was approved by the
Medical University of South Carolina Institutional Animal Care
and Use Committee.
AUTHOR CONTRIBUTIONS
RL and CR participated in study design, performing experiments,
data interpretation, and manuscript preparation. GC, BP,
MZ, and CW participated in performing experiments. MB
participated in performing experiments and in editing the
manuscript. RS participated in editing the manuscript. SH
Frontiers in Pharmacology | www.frontiersin.org 12 April 2017 | Volume 8 | Article 174
Lee et al. Caveolin-1 and PPARγ in Monocyte Adipogenesis
participated in study design, data interpretation, and editing
the manuscript. KH participated in data interpretation. ET
participated in study design, data interpretation, manuscript
preparation, and editing the manuscript. All authors read and
approved the final manuscript.
FUNDING
This work was supported by grants: NIH NIAMS R01
AR062078 and a grant from the Scleroderma Foundation (to
ET); USARMY/USAMRAA W81XWH-11-1-0508 (to SH); NIH
NIAMS P60 AR049459 (Multidisciplinary Clinical Research
Center) (to RS); and an NIH NCRR Construction Grant C06
RR015455. ET also received the Marta Max Award from the
Scleroderma Foundation.
ACKNOWLEDGMENTS
The authors thank Kelley Kasdasz and Dana Rosson for
recruiting donors and collecting blood samples.
REFERENCES
August, P., and Suthanthiran, M. (2003). Transforming growth factor
beta and progression of renal disease. Kidney Int. Suppl. 87, S99–S104.
doi: 10.1046/j.1523-1755.64.s87.15.x
Berger, J. P., Akiyama, T. E., and Meinke, P. T. (2005). PPARs: therapeutic
targets for metabolic disease. Trends Pharmacol. Sci. 26, 244–251.
doi: 10.1016/j.tips.2005.03.003
Bernatchez, P. N., Bauer, P. M., Yu, J., Prendergast, J. S., He, P., and Sessa, W.
C. (2005). Dissecting the molecular control of endothelial NO synthase by
caveolin-1 using cell-permeable peptides. Proc. Natl. Acad. Sci. U.S.A. 102,
761–766. doi: 10.1073/pnas.0407224102
Berry, R., and Rodeheffer, M. S. (2013). Characterization of the adipocyte cellular
lineage in vivo. Nat. Cell Biol. 15, 302–308. doi: 10.1038/ncb2696
Bucci, M., Gratton, J. P., Rudic, R. D., Acevedo, L., Roviezzo, F., Cirino, G.,
et al. (2000). In vivo delivery of the caveolin-1 scaffolding domain inhibits
nitric oxide synthesis and reduces inflammation. Nat. Med. 6, 1362–1367.
doi: 10.1038/82176
Burgermeister, E., Friedrich, T., Hitkova, I., Regel, I., Einwächter, H.,
Zimmermann, W., et al. (2011). The Ras inhibitors caveolin-1 and docking
protein 1 activate peroxisome proliferator-activated receptor γ through spatial
relocalization at helix 7 of its ligand-binding domain. Mol. Cell. Biol. 31,
3497–3510. doi: 10.1128/MCB.01421-10
Christopeit, M., Schendel, M., Föll, J., Muller, L. P., Keysser, G., and Behre, G.
(2008). Marked improvement of severe progressive systemic sclerosis after
transplantation of mesenchymal stem cells from an allogeneic haploidentical-
related donor mediated by ligation of CD137L. Leukemia 22, 1062–1064.
doi: 10.1038/sj.leu.2404996
Cinti, S., Mitchell, G., Barbatelli, G., Murano, I., Ceresi, E., Faloia, E., et al.
(2005). Adipocyte death defines macrophage localization and function in
adipose tissue of obese mice and humans. J. Lipid Res. 46, 2347–2355.
doi: 10.1194/jlr.M500294-JLR200
Collins, A. R., Meehan, W. P., Kintscher, U., Jackson, S., Wakino, S., Noh, G.,
et al. (2001). Troglitazone inhibits formation of early atherosclerotic lesions
in diabetic and nondiabetic low density lipoprotein receptor-deficient mice.
Arterioscler. Thromb. Vasc. Biol. 21, 365–371. doi: 10.1161/01.ATV.21.3.365
Crossno, J. T. Jr., Majka, S. M., Grazia, T., Gill, R. G., and Klemm, D. J.
(2006). Rosiglitazone promotes development of a novel adipocyte population
from bone marrow-derived circulating progenitor cells. J. Clin. Invest. 116,
3220–3228. doi: 10.1172/JCI28510
Del Galdo, F., Sotgia, F., De Almeida, C. J., Jasmin, J. F., Musick, M., Lisanti, M.
P., et al. (2008). Decreased expression of caveolin 1 in patients with systemic
sclerosis: crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum. 58,
2854–2865. doi: 10.1002/art.23791
Dubland, J. A., and Francis, G. A. (2015). Lysosomal acid lipase: at the crossroads
of normal and atherogenic cholesterol metabolism. Front. Cell Dev. Biol. 3:3.
doi: 10.3389/fcell.2015.00003
Evans, R. M., Barish, G. D., and Wang, Y. X. (2004). PPARs and the complex
journey to obesity. Nat. Med. 10, 355–361. doi: 10.1038/nm1025
Ghosh, A. K., Bhattacharyya, S., Lakos, G., Chen, S. J., Mori, Y., and Varga, J.
(2004). Disruption of transforming growth factor β signaling and profibrotic
responses in normal skin fibroblasts by peroxisome proliferator-activated
receptor γ. Arthritis Rheum. 50, 1305–1318. doi: 10.1002/art.20104
Guiducci, S., Porta, F., Saccardi, R., Guidi, S., Ibba-Manneschi, L.,Manetti, M., et al.
(2010). Autologousmesenchymal stem cells foster revascularization of ischemic
limbs in systemic sclerosis: a case report. Ann. Intern. Med. 153, 650–654.
doi: 10.7326/0003-4819-153-10-201011160-00007
Hohsfield, L. A., and Humpel, C. (2015). Intravenous infusion of monocytes
isolated from 2-week-old mice enhances clearance of Beta-amyloid
plaques in an Alzheimer mouse model. PLoS ONE 10:e0121930.
doi: 10.1371/journal.pone.0121930
Hong, K. M., Belperio, J. A., Keane, M. P., Burdick, M. D., and Strieter, R.
M. (2007). Differentiation of human circulating fibrocytes as mediated by
transforming growth factor-β and peroxisome proliferator-activated receptor
γ. J. Biol. Chem. 282, 22910–22920. doi: 10.1074/jbc.M703597200
Hong, K. M., Burdick, M. D., Phillips, R. J., Heber, D., and Strieter, R. M. (2005).
Characterization of human fibrocytes as circulating adipocyte progenitors and
the formation of human adipose tissue in SCID mice. FASEB J. 19, 2029–2031.
doi: 10.1096/fj.05-4295fje
Jiang, C., Ting, A. T., and Seed, B. (1998). PPAR-γ agonists inhibit production of
monocyte inflammatory cytokines. Nature 391, 82–86. doi: 10.1038/35154
Jiang, M., Zhang, L., Ma, X., Hu, W., Chen, Y., Yu, M., et al. (2013). Tamoxifen
inhibits macrophage FABP4 expression through the combined effects of the GR
and PPARγ pathways. Biochem. J. 454, 467–477. doi: 10.1042/BJ20130580
Kasper, M., Reimann, T., Hempel, U., Wenzel, K. W., Bierhaus, A., Schuh, D.,
et al. (1998). Loss of caveolin expression in type I pneumocytes as an indicator
of subcellular alterations during lung fibrogenesis. Histochem. Cell Biol. 109,
41–48. doi: 10.1007/s004180050200
Keyszer, G., Christopeit, M., Fick, S., Schendel, M., Taute, B. M., Behre, G., et al.
(2011). Treatment of severe progressive systemic sclerosis with transplantation
of mesenchymal stromal cells from allogeneic related donors: report of five
cases. Arthritis Rheum. 63, 2540–2542. doi: 10.1002/art.30431
Kintscher, U., Wakino, S., Bruemmer, D., Goetze, S., Graf, K., Hsueh, W. A., et al.
(2002). TGF-β1 induces peroxisome proliferator-activated receptor γ1 and γ2
expression in human THP-1 monocytes. Biochem. Biophys. Res. Commun. 297,
794–799. doi: 10.1016/S0006-291X(02)02264-7
Krishnan, E., and Furst, D. E. (2005). Systemic sclerosis mortality
in the United States: 1979-1998. Eur. J. Epidemiol. 20, 855–861.
doi: 10.1007/s10654-005-2210-5
Kuwana, M., Okazaki, Y., Kodama, H., Izumi, K., Yasuoka, H., Ogawa, Y., et al.
(2003). Human circulating CD14+ monocytes as a source of progenitors
that exhibit mesenchymal cell differentiation. J. Leukoc. Biol. 74, 833–845.
doi: 10.1189/jlb.0403170
Laing, T. J., Gillespie, B. W., Toth, M. B., Mayes, M. D., Gallavan, R. H. Jr., Burns,
C. J., et al. (1997). Racial differences in scleroderma amongwomen inMichigan.
Arthritis Rheum. 40, 734–742. doi: 10.1002/art.1780400421
Lázaro, I., Ferre, R., Masana, L., and Cabre, A. (2013). Akt and ERK/Nrf2
activation by PUFA oxidation-derived aldehydes upregulates FABP4
expression in human macrophages. Atherosclerosis 230, 216–222.
doi: 10.1016/j.atherosclerosis.2013.07.043
Lee, R., Perry, B., Heywood, J., Reese, C., Bonner, M., Hatfield, C. M., et al.
(2014a). Caveolin-1 regulates chemokine receptor 5-mediated contribution
of bone marrow-derived cells to dermal fibrosis. Front. Pharmacol. 5:140.
doi: 10.3389/fphar.2014.00140
Lee, R., Reese, C., Bonner, M., Tourkina, E., Hajdu, Z., Riemer, E. C., et al. (2014b).
Bleomycin delivery by osmotic mini-pump: similarity to human scleroderma
Frontiers in Pharmacology | www.frontiersin.org 13 April 2017 | Volume 8 | Article 174
Lee et al. Caveolin-1 and PPARγ in Monocyte Adipogenesis
interstitial lung disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 306, L736–L748.
doi: 10.1152/ajplung.00210.2013
Lee, R., Reese, C., Bonner, M., Tourkina, E., Hajdu, Z., Riemer, E. C., et al. (2014c).
Bleomycin delivery by osmotic minipump: similarity to human scleroderma
interstitial lung disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 306, L736–L748.
doi: 10.1152/ajplung.00210.2013
Lee, R., Reese, C., Perry, B., Heywood, J., Bonner, M., Zemskova, M., et al.
(2015). Enhanced chemokine-receptor expression, function, and signaling in
healthy African American and scleroderma-patient monocytes are regulated by
caveolin-1. Fibrogenesis Tissue Repair 8, 11. doi: 10.1186/s13069-015-0028-7
Leroy, E. C., Black, C., Fleischmajer, R., Jablonska, S., Krieg, T., Medsger, T.
A., et al. (1988). Scleroderma (systemic sclerosis): classification, subsets and
pathogenesis. J. Rheumatol. 15, 202–205.
Llaverias, G., Vázquez-Carrera, M., Sánchez, R. M., Noé, V., Ciudad, C. J., Laguna,
J. C., et al. (2004). Rosiglitazone upregulates caveolin-1 expression in THP-
1 cells through a PPAR-dependent mechanism. J. Lipid Res. 45, 2015–2024.
doi: 10.1194/jlr.M400049-JLR200
Marangoni, R. G., Korman, B. D., Wei, J., Wood, T. A., Graham, L. V., Whitfield,
M. L., et al. (2015). Myofibroblasts in murine cutaneous fibrosis originate
from adiponectin-positive intradermal progenitors. Arthritis Rheumatol. 67,
1062–1073. doi: 10.1002/art.38990
Mayes, M. D. (2003). Endothelin and endothelin receptor antagonists in systemic
rheumatic disease. Arthritis Rheum. 48, 1190–1199. doi: 10.1002/art.10895
Nagajyothi, F., Desruisseaux, M. S., Thiruvur, N., Weiss, L. M., Braunstein, V. L.,
Albanese, C., et al. (2008). Trypanosoma cruzi infection of cultured adipocytes
results in an inflammatory phenotype. Obesity (Silver. Spring). 16, 1992–1997.
doi: 10.1038/oby.2008.331
Nietert, P. J., Mitchell, H. C., Bolster, M. B., Shaftman, S. R., Tilley, B. C., and Silver,
R. M. (2006). Racial variation in clinical and immunological manifestations of
systemic sclerosis. J. Rheumatol. 33, 263–268.
Reese, C., Lee, R., Bonner, M., Perry, B., Heywood, J., Silver, R. M., et al. (2014a).
Fibrocytes in the fibrotic lung: altered phenotype detected by flow cytometry.
Front. Pharmacol. 5:141. doi: 10.3389/fphar.2014.00141
Reese, C., Perry, B., Heywood, J., Bonner, M., Visconti, R. P., Lee, R., et al.
(2014b). Caveolin-1 deficiency may predispose African Americans to systemic
sclerosis-related interstitial lung disease. Arthritis Rheumatol. 66, 1909–1919.
doi: 10.1002/art.38572
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., and Glass, C. K. (1998).
The peroxisome proliferator-activated receptor-γ is a negative regulator of
macrophage activation. Nature 391, 79–82. doi: 10.1038/34178
Rochford, J. J. (2010). Molecular mechanisms controlling human adipose tissue
development: insights from monogenic lipodystrophies. Expert Rev. Mol. Med.
12, e24. doi: 10.1017/S1462399410001547
Scuderi, N., Ceccarelli, S., Onesti, M. G., Fioramonti, P., Guidi, C., Romano,
F., et al. (2013). Human adipose-derived stromal cells for cell-based
therapies in the treatment of systemic sclerosis. Cell Transplant. 22, 779–795.
doi: 10.3727/096368912X639017
Silver, R. M., Bogatkevich, G., Tourkina, E., Nietert, P. J., and Hoffman, S. (2012).
Racial differences between blacks and whites with systemic sclerosis. Curr.
Opin. Rheumatol. 24, 642–648. doi: 10.1097/BOR.0b013e328356d9dc
Spiegelman, B. M. (1998). PPAR-gamma: adipogenic regulator
and thiazolidinedione receptor. Diabetes 47, 507–514.
doi: 10.2337/diabetes.47.4.507
Subcommittee (1980). Preliminary criteria for the classification of systemic
sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American
Rheumatism Association Diagnostic and Therapeutic Criteria Committee.
Arthritis Rheum. 23, 581–590.
Tager, R. E., and Tikly, M. (1999). Clinical and laboratory manifestations
of systemic sclerosis (scleroderma) in Black South Africans. Rheumatology
(Oxford). 38, 397–400. doi: 10.1093/rheumatology/38.5.397
Tontonoz, P., Nagy, L., Alvarez, J. G., Thomazy, V. A., and Evans, R. M. (1998).
PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized
LDL. Cell 93, 241–252. doi: 10.1016/S0092-8674(00)81575-5
Tourkina, E., Bonner, M., Oates, J., Hofbauer, A., Richard, M., Znoyko, S., et al.
(2011). Alteredmonocyte and fibrocyte phenotype and function in scleroderma
interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide.
Fibrogenesis Tissue Repair 4:15. doi: 10.1186/1755-1536-4-15
Tourkina, E., Gooz, P., Pannu, J., Bonner, M., Scholz, D., Hacker, S., et al.
(2005). Opposing effects of protein kinase Calpha and protein kinase Cǫ on
collagen expression by human lung fibroblasts are mediated via MEK/ERK and
caveolin-1 signaling. J. Biol. Chem. 280, 13879–13887. doi: 10.1074/jbc.M4125
51200
Tourkina, E., Richard, M., Gooz, P., Bonner, M., Pannu, J., Harley, R., et al.
(2008). Antifibrotic properties of caveolin-1 scaffolding domain in vitro
and in vivo. Am. J. Physiol. Lung Cell. Mol. Physiol. 294, L843–L861.
doi: 10.1152/ajplung.00295.2007
Tourkina, E., Richard, M., Oates, J., Hofbauer, A., Bonner, M., Gooz, P., et al.
(2010). Caveolin-1 regulates leucocyte behaviour in fibrotic lung disease. Ann.
Rheum. Dis. 69, 1220–1226. doi: 10.1136/ard.2009.117580
Wang, X. M., Zhang, Y., Kim, H. P., Zhou, Z., Feghali-Bostwick, C. A.,
Liu, F., et al. (2006). Caveolin-1: a critical regulator of lung fibrosis in
idiopathic pulmonary fibrosis. J. Exp. Med. 203, 2895–2906. doi: 10.1084/jem.
20061536
Wei, J., Ghosh, A. K., Sargent, J. L., Komura, K., Wu, M., Huang, Q. Q.,
et al. (2010). PPARγ downregulation by TGFss in fibroblast and impaired
expression and function in systemic sclerosis: a novel mechanism for
progressive fibrogenesis. PLoS ONE 5:e13778. doi: 10.1371/journal.pone.
0013778
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 Lee, Reese, Carmen-Lopez, Perry, Bonner, Zemskova, Wilson,
Helke, Silver, Hoffman and Tourkina. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 14 April 2017 | Volume 8 | Article 174
